Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Corifollitropin alfa - Merck & Co

Next Previous
X
Search
Drug Profile

Corifollitropin alfa - Merck & Co

Alternative Names: Elonva; Follitropin-stimulating hormone long-acting; FSH long-acting; FSH-CTP; Long-acting follicle-stimulating hormone; MK-8962; ORG-36286; SCH-900962

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Organon
  • Developer Merck & Co; Universitair Ziekenhuis Brussel
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility; Hypogonadism
  • Phase III Polycystic ovary syndrome

Most Recent Events

  • 31 Dec 2022 Merck Sharp & Dohme completes a phase III trial in Polycystic ovary syndrome in Belgium (SC) (NCT03197077)
  • 27 Jul 2022 Launched for Hypogonadism (In adolescents) in Denmark (SC)
  • 27 Jul 2022 Launched for Hypogonadism (In adolescents) in Italy (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top